Stacy Ann Coen - Nov 15, 2023 Form 4 Insider Report for ImmunoGen, Inc. (IMGN)

Signature
/s/ Renee Lentini, Attorney-in-Fact
Stock symbol
IMGN
Transactions as of
Nov 15, 2023
Transactions value $
-$979,845
Form type
4
Date filed
11/17/2023, 07:52 PM
Previous filing
Sep 11, 2023
Next filing
Dec 5, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IMGN Common Stock Options Exercise $103K +21K +56.77% $4.92 58K Nov 15, 2023 Direct F1
transaction IMGN Common Stock Options Exercise $40.8K +5.3K +9.15% $7.69 63.3K Nov 15, 2023 Direct F1
transaction IMGN Common Stock Sale -$421K -26.3K -41.56% $16.01 37K Nov 15, 2023 Direct F1, F2
transaction IMGN Common Stock Options Exercise $15.7K +3.2K +8.66% $4.92 40.2K Nov 16, 2023 Direct F1
transaction IMGN Common Stock Options Exercise $6.92K +900 +2.24% $7.69 41.1K Nov 16, 2023 Direct F1
transaction IMGN Common Stock Sale -$65.6K -4.1K -9.98% $16.01 37K Nov 16, 2023 Direct F1, F3
transaction IMGN Common Stock Options Exercise $10.8K +2.2K +5.95% $4.92 39.2K Nov 17, 2023 Direct F1
transaction IMGN Common Stock Options Exercise $585K +76K +194.1% $7.69 115K Nov 17, 2023 Direct F1
transaction IMGN Common Stock Sale -$1.26M -78.2K -67.91% $16.05 37K Nov 17, 2023 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IMGN Stock Option (Right to Buy) Options Exercise $0 -21K -27.9% $0.00 54.2K Nov 15, 2023 Common Stock 21K $4.92 Direct F1, F5
transaction IMGN Stock Option (Right to Buy) Options Exercise $0 -5.3K -3.33% $0.00 154K Nov 15, 2023 Common Stock 5.3K $7.69 Direct F1, F6
transaction IMGN Stock Option (Right to Buy) Options Exercise $0 -3.2K -5.9% $0.00 51K Nov 16, 2023 Common Stock 3.2K $4.92 Direct F1, F5
transaction IMGN Stock Option (Right to Buy) Options Exercise $0 -900 -0.59% $0.00 153K Nov 16, 2023 Common Stock 900 $7.69 Direct F1, F6
transaction IMGN Stock Option (Right to Buy) Options Exercise $0 -2.2K -4.31% $0.00 48.8K Nov 17, 2023 Common Stock 2.2K $4.92 Direct F1, F5
transaction IMGN Stock Option (Right to Buy) Options Exercise $0 -76K -49.75% $0.00 76.8K Nov 17, 2023 Common Stock 76K $7.69 Direct F1, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Effected pursuant to a trading plan adopted on August 10, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
F2 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.03, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within these ranges.
F3 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.02, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within these ranges.
F4 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.17, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within these ranges.
F5 This option was granted on June 1, 2020 and is exercisable as to 25% on the first year anniversary of the grant and 6.25% quarterly for the subsequent three years.
F6 This option was granted on February 5, 2021 and is exercisable as to 25% on the first year anniversary of the grant and 6.25% quarterly for the subsequent three years.